AzTrials
AzTrials

BPPVNCT06228196

Cohort Study of Clinical and Neuroimaging Characteristics for BPPV Patients in China

An observational study of BPPV and Vertigo, run by First Affiliated Hospital Xi'an Jiaotong University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The main objective is to analyze the abnormality of physical condition, mental health and blood examination of the patients with benign paroxysmal positional vertigo (BPPV). Besides, the investigators aim to establish a database of BPPV based on multimodal magnetic resonance imaging data in the brain to identify… Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
BPPV, Vertigo, Vertigo, Peripheral
What is being tested?
Simultaneous cortico-spinal magnetic resonance imaging, Serum
Type of treatment
Medical device
How many people
150 participants
Where
1 siteChina
Study dates
8 Jan 2024to 30 Sep 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: The study will be carried out in the First Affiliated Hospital Xi'an Jiaotong University for patients who had diagnosis of BPPV by the Dix-Hallpike maneuver or Supine Roll test. The healthy control population will be searched in the primary care services, media and social networks. All participants will sign informed consent.

Who may be able to join

  • Confirmed diagnosis of BPPV/Healthy subjects who have not had BPPV

Who cannot join

  • History of organic diseases in central nervous system and mental disorder, such as tumors, infections, depressive disorder, schizophrenia, etc. Claustrophobic

Trial locations and contacts

1 site in 1 country.

Ming Zhang, PhD contact

+8618991232265

zmmri@163.com

China1 site, 1 recruiting
  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710061

    Yuan Wang, M.D., 0086-13324598144, wangyuan8003@126.com

    Ming Zhang, PhD, 0086-18991232265, zmmri@163.com

    Recruiting

Other trials in China

About this study

The main objective is to analyze the abnormality of physical condition, mental health and blood examination of the patients with benign paroxysmal positional vertigo (BPPV). Besides, the investigators aim to establish a database of BPPV based on multimodal magnetic resonance imaging data in the brain to identify high-risk patients with residual dizziness (RD) and systematically establish the comprehensive assessment system for the precise diagnosis, treatment and recovery of RD, optimize the tactics of BPPV management in China.

Read the detailed description

This is an observational, longitudinal, and single-center study. Confirmed BPPV cases will complete the following programs before and after 1 and 6 months of treatment for exploring biological mechanism and predictive biomarkers of BPPV: 1) fill in the behavioral psychological scales, 2) submit blood samples at a local laboratory, 3) receive 3 times brain MRI scan. The healthy controls will complete the same programs as BPPV-group mentioned above only at the time of inclusion. The investigators will establish the brain MRI database containing neuropsychological scales and blood parameters of BPPV in China.

Being tested
Simultaneous cortico-spinal magnetic resonance imaging, Serum
Keywords
BPPV, residual dizziness, Vertigo, Neuroimaging, Epidemic
Medical subject headings
Vertigo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Simultaneous cortico-spinal magnetic resonance imaging, SerumDevice

    Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.

Study groups in NCT06228196
Study groupRoleWhat they receive
BPPV patientsConfirmed diagnosis of BPPV
Receives: Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum
Healthy controlsHealthy subjects who have not had BPPV
Receives: Device: Simultaneous cortico-spinal magnetic resonance imaging, Serum

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Differences between patients with BPPV and control group in brain structure

    The changes of brain volume (mm3) are evaluated by structural MRI

    Measured: baseline and 1 and 6 months

  2. Differences between two groups in brain function

    The changes of brain functional connectivity intensity are evaluated by functional MRI

    Measured: baseline and 1 and 6 months

  3. Changes on vertigo symptoms

    Vertigo is assessed with the Dizziness Handicap Inventory (DHI Scale)

    Measured: baseline and 1 and 6 months

  4. Changes on vertigo symptoms

    Vertigo is also assessed with the Activities-specific Balance Confidence Scale (ABC Scale)

    Measured: baseline and 1 and 6 months

  5. Changes on vertigo symptoms

    Vertigo is also assessed with the Visual Vertigo Analogue Scale (VVAS)

    Measured: baseline and 1 and 6 months

  6. Difference in blood markers between the two groups

    All subjects underwent fasting vein blood collection of about 5 ml at about 8 a.m. Blood indices related to BPPV and related clinical symptoms were screened, the inflammatory index is interleukin-6(IL-6)

    Measured: baseline and 1 and 6 months

  7. Difference in blood markers between the two groups

    Immunology-related index in the blood sample is superoxide dismutase (SOD)

    Measured: baseline and 1 and 6 months

  8. Difference in blood markers between the two groups

    Inflammatory index in the blood sample is neutrophils/lymphocytes

    Measured: baseline and 1 and 6 months

Secondary outcomes (8)
  1. Differences in Fatigue between the two groups

    Fatigue is assessed with the Multidimensional Fatigue Inventory (MFI). A higher score represents a worse outcome. The MFI is a 20-item self-report instrument covering four dimensions (general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity) designed to measure fatigue.

    Measured: baseline and 1 and 6 months

  2. Differences in Sleep between the two groups

    Sleep quality is assessed with Pittsburgh Sleep Quality Index (PSQI). A higher score corresponding to a worse sleep quality.

    Measured: baseline and 1 and 6 months

  3. Differences in cognition between the two groups

    The cognition is assessed with Montreal Cognitive Assessment (MoCA). Higher scores (0-30) are related to a better performance.

    Measured: baseline and 1 and 6 months

  4. Differences in executive function between the two groups

    The executive function is assessed with Trail Making Test A and B. Participants are asked to connect sequential numbers (TMT-A) and interconnect sequential numbers and letters (TMT-B).

    Measured: baseline and 1 and 6 months

  5. Difference in anxiety between the two groups

    Anxiety is assessed with Beck Anxiety Inventory (BAI). A higher score corresponding to more severe anxiety symptoms.

    Measured: baseline and 1 and 6 months

  6. Difference in depression between the two groups

    Depression is assessed with the Patient Health Questionnaire-9 (PHQ-9). A higher score corresponding to more severe depression symptoms.

    Measured: baseline and 1 and 6 months

  7. Differences in verbal memory and working memory between the two groups

    Verbal memory is assessed with the Auditory Verbal Learning Test (AVLT). A 12-word list are read by examiner three times and participants are asked to recall them followed by each presentation, which was called "immediate recall". The "short delayed recall" and "long delayed recall" ask the participants to recall the above 12-word list 5 minutes and 20 minutes later, the correctly recalled number of words are recorded. Finally, the subjects are instructed to recognize the learned words from a 24-words list which consisted of above learned 12-words list and a new unlearned 12-words list. Working memory is assessed with the Digit Span Backward. Participants are asked to repeat the numbers in the reverse order the examiner read them aloud and a higher score corresponding to a better outcome.

    Measured: baseline and 1 and 6 months

  8. Differences in auditory attention between the two groups

    Auditory attention is assessed with the Digit Span Forward. Participants are asked to repeat the numbers in the order the examiner read them aloud and a higher score corresponding to a better outcome.

    Measured: baseline and 1 and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2024
  2. Study start8 Jan 2024
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completion30 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06228196
Sponsor's protocol ID
XJTU1AF2023LSK-566
Status last verified
Feb 2024
First submitted
8 Jan 2024
Last updated
26 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of BPPV and Vertigo, run by First Affiliated Hospital Xi'an Jiaotong University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Yuan Wang, M.D. (0086-13324598144, wangyuan8003@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Differences between patients with BPPV and control group in brain structure (time frame: baseline and 1 and 6 months). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in